CHF Solutions Announces Deployment of Aquadex Systems to Hospitals in the Southeast to Treat COVID-19 Patients
October 27 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced that it has shipped Aquadex™ product to medical
facilities in Tennessee and South Carolina to treat critically ill
patients suffering from COVID-19.
“As COVID-19 continues to impact patients and providers across
the country, we remain dedicated to providing medical professionals
with the tools they need to quickly, effectively and gently treat
patients,” said John Erb, CEO of CHF Solutions. “We continue to see
a positive effect on patient outcomes with the use of Aquadex to
manage fluid status in COVID-19 patients, and we’ll continue to
respond to providers facing surges of patients and increased
demands for access to Aquadex.”
Most COVID-19 patients who are admitted to the intensive care
unit present or develop respiratory failure, heart related issues,
and/or some degree of acute kidney injury, referred to as AKI. The
publication from Baylor University Medical Center, titled,
“SARS-CoV-2 (COVID-19) and Intravascular Volume Management
Strategies in the Critically Ill” identified isolated
ultrafiltration as an optimal strategy that primarily focuses on
fluid extraction and optimization of volume status to treat
COVID-19 patients.1 Several hospitals across the country have
included a simplified ultrafiltration system, such as Aquadex
therapy, into their treatment protocol for fluid management for
COVID-19 patients, especially when dialysis equipment and staff are
limited. The simple, flexible and smart system allows for a 4:1
patient to nurse ratio, meaning the nurse does not have to remain
by the bedside for the entire treatment, thereby preserving vital
staff and equipment for patients requiring dialysis.
-
https://pubmed.ncbi.nlm.nih.gov/32336959/
About CHF SolutionsCHF Solutions, Inc. (Nasdaq:
CHFS) is a medical device company dedicated to improving the lives
of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow SystemThe Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
the Aquadex system to treat patients affected with COVID-19.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024